gibco
by life technologies

Recombinant Mouse Interleukin–4 (IL–4)

Publication Number MAN0004195 **Rev.** 2.00

Catalog Number:	PMC0045	PMC0046	PMC0043
Quantity:	10 µg	25 µg	1 mg
Lot Number:	See product label.		
Molecular Weight:	13.5 kDa (120 amino acid residues)		
Purity:	>95% as determined by SDS–PAGE and RP–HPLC analyses.		
Biological Activity:	ED_{50} ≤2 ng/mL (corresponding to a specific activity of ≥5 × 10^5 units/mg), determined by measuring the dose–dependent proliferation of murine HT–2 cells. The optimal concentration for each specific application should be determined by an initial dose-response assay.		
Formulation:	Lyophilized from a concentrated (1 mg/mL) solution in 10 mM Na-Citrate, pH 3.0.		
Sterility:	Sterile filtered prior to lyophilization.		
Production:	Recombinant mouse IL–4 is produced in *E. coli* and purified via sequential chromatography.		
Reconstitution Recommendation:	We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Lyophilized mIL–4 should be reconstituted in sterile, deionized water to a concentration of 0.1–1.0 mg/mL to regain full activity. For long term storage, it is recommended to add a carrier protein, such as 0.1% HSA or BSA		
Suggested Working Dilutions:	The optimal concentration should be determined for each specific application.		
Storage:	This lyophilized preparation is stable at room temperature for 3 weeks, but should be stored desiccated below -18°C. Upon reconstitution, the preparation is stable at 4°C for up to 1 week, but should be stored below –18°C for long term storage. Avoid repeated freeze/thaw cycles.		
Expiration Date:	See product label.		
References:	Bockenstedt, L.K., I. Kang, C. Chang, D. Persing, A. Hayday, and S.W. Barthold (2001) CD4(+) T helper 1 cells facilitate regression of murine Lyme carditis. Infection and Immunity 69(9):5264–5269. Bryson, J.S., C.D. Jennings, D.M. Lowery, S.L. Carlson, D.L. Pflugh, B.E. Caywood, and A.M. Kaplan (1999) Rejection of an MHC class II negative tumor following induction of murine syngeneic graft-versus-host disease. Bone Marrow Transplant. 23(4):363–372. Burgess, W., K. Jesse, Q.S. Tang, S.R. Broussard, R. Dantzer and K.W. Kelley (2003) Insulin-like growth factor–I and the cytokines IL–3 and IL–4 promote survival of progenitor myeloid cells by different mechanisms. J. Neuroimmunol. 135(1-2):82–90. Callard, R., and A. Gearing (1994). The Cytokines and Their Receptors: IL–4. Academic Press Limited. San Diego, CA. pp. 53–58. Chen, X.P., X.H. Ding, and R.A. Daynes (2000) Ganglioside control over IL–4 priming and cytokine production in activated T cells. Cytokine 12(7):972–985. Gallucci, S., M. Lolkema, and P. Matzinger (1999) Natural adjuvants: Endogenous activators of dendritic cells. Nature Medicine 5(11):1249–1255. Giese, N.A., L. Gabriele, T.M. Doherty, D.M. Klinman, L. Tadesse–Heath, C. Contursi, S.L. Epstein, and H.C. Morse 3rd (1997) Interferon (IFN) consensus sequence-binding protein, a transcription factor of the IFN regulatory factor family, regulates immune responses in vivo through control of interleukin 12 expression. J. Exp. Med. 186(9):1535–1546. Hoffman, R.A., R.S. Mahidhara, A.S. Wolf-Johnston, L. Lu, A.W. Thomson, and R.L. Simmons (2002) Differential modulation of CD4 and CD8 T–cell proliferation by induction of nitric oxide synthesis in antigen presenting cells. Transplantation 74(6):836–845. Infante-Duarte, C., H.F. Horton, M.C. Byrne, and T. Kamradt (2000) Microbial lipopeptides induce the production of IL-17 in Th cells. J. Immunol. 165(11):6107–6115. Keane-Myers, A. and S.P. Nickell (1995) Role of IL-4 and IFN–gamma in modulation of immunity to Borrelia burgdorferi in mice. J. Immunol. 155(4):2020–2028.		

References, Continued:

Kelly, E., A. Won, Y. Refaeli, and L. Van Parijs (2002) IL-2 and related cytokines can promote T cell survival by activating AKT. J. Immunol. 168(2):597–603.

Löhning, M., A. Stroehmann, A. Coyle, J. Grogan, S. Lin, J.-C. Gutierrez-Ramos, D. Levinson, A. Radbruch, and T. Kamradt (1998) T1/ST2 is preferentially expressed on murine Th2 cells, independent of interleukin 4, interleukin 5, and interleukin 10, and important for Th2 effector function. Proc. Nat'l. Acad. Sci. 95(12):6930–6935.

Meisel, C., K. Bonhagen, M. Lohning, A.J. Coyle, J.C. Gutierrez-Ramos, A. Radbruch, and T. Kamradt (2001) Regulation and function of T1/ST2 expression on CD4(+) T cells: Induction of type 2 cytokine production by T1/ST2 cross-linking. J. Immunol. 166(5):3143–3150.

Mirmonsef, P., C.P. Shelburne, C.F. Yeatman, H.J. Chong, and J.J. Ryan (1999) Inhibition of Kit expression by IL–4 and IL-10 in murine mast cells: Role of STAT6 and phosphatidylinositol 3'-kinase. J. Immunol. 163(5):2530–2539.

Serreze, D.V., M.A. Pierce, C.M. Post, H.D. Chapman, H. Savage, R.T. Bronson, P.B. Rothman and G.A. Cox (2003) Paralytic autoimmune myositis develops in nonobese diabetic mice made Th1 cytokine-deficient by expression of an IFN-gamma receptor beta-chain transgene. J. Immunol. 170(5):2742–2749.

Shelburne, C.P., and J.J. Ryan (2000) Combined stimulation with the T helper cell type 2 cytokines interleukin (IL)–4 and IL-10 induces mouse mast cell apoptosis. J. Exp. Med. 192(8):1093–1103.

Venkataraman, C., G. Schaefer, and U. Schindler (2000) Cutting edge: Chandra, a novel four-transmembrane domain protein differentially expressed in helper type 1 lymphocytes. J. Immunol. 165(2):632–636.

Wang, D., J. Zamorano, A.D. Keegan, and M. Boothby (1997) HMG-I(Y) phosphorylation status as a nuclear target regulated through insulin receptor substrate-1 and the I4R motif of the interleukin-4 receptor. J. Biol. Chem. 272(40):25083–25090.

Willis, M.S, L.W. Klassen, D.J. Tuma, M.F. Sorrell, and G.M. Thiele (2002) In vitro exposure to malondialdehyde-acetaldehyde adducted protein inhibits cell proliferation and viability. Alcholism-Clinical and Experimental Research 26 (2):158–164.

Yeatman, C.F., S.M. Jacobs-Helber, P. Mirmonsef, S.R. Gillespie, L.A. Bouton, H.A. Collins, S.T. Sawyer, C.P. Shelburne, and J.J. Ryan (2000) Combined stimulation with the T helper cell type 2 cytokines interleukin (IL)–4 and IL–10 induces mouse mast cell apoptosis. J. Exp. Med. 192(8):1093–1103.

Explanation of Symbols

The symbols present on the product label are explained below:

Symbol	Description
REF	Catalog Number
RUO	Research Use Only
	Use by
	Manufacturer
[–]	Without, does not contain
	Protect from light
	Directs the user to consult instructions for use (IFU), accompanying the product.

Symbol	Description
LOT	Batch code
IVD	In vitro diagnostic medical device
	Temperature limitation
EC REP	European Community authorized representative
[+]	With, contains
⚠	Consult accompanying documents

Limited Use Label License: Research Use Only

The purchase of this product conveys to the purchaser the limited, non-transferable right to use the purchased amount of the product only to perform internal research for the sole benefit of the purchaser. No right to resell this product or any of its components is conveyed expressly, by implication, or by estoppel. This product is for internal research purposes only and is not for use in commercial applications of any kind, including, without limitation, quality control and commercial services such as reporting the results of purchaser's activities for a fee or other form of consideration. For information on obtaining additional rights, please contact outlicensing@lifetech.com or Out Licensing, Life Technologies, 5791 Van Allen Way, Carlsbad, California 92008.

For Research Use Only. Caution: Not for human or animal therapeutic or diagnostic use.

Manufactured under ISO 13485 Quality Standard

Manufacturing site: 7335 Executive Way | Frederick, MD 21704 | Toll Free in USA 800.955.6288 .

For support visit www.lifetechnologies.com/support or email techsupport@lifetech.com

www.lifetechnologies.com

Revision Date 19 May 2011

life technologies™